The collaboration will support Alzheimer's, lipid metabolism, and cardiovascular research using DiamiR's CAP- and CLEP-certified testing infrastructure
Key Highlights
- New APOE Genotyping Partnership: DiamiR Biosciences, a subsidiary of Niki BioSolutions, contracted with Progressive Medical Research to deliver APOE genotyping services.
- CAP- and CLEP-Certified Infrastructure: The partnership gives PMR access to DiamiR's certified clinical testing infrastructure for its study frameworks.
- Supports Multiple Research Areas: The genetic insights will support Alzheimer's disease, lipid metabolism, and cardiovascular research initiatives.
Niki BioSolutions, Inc. (NASDAQ: NIKI) revealed that DiamiR Biosciences, its subsidiary, has contracted with Progressive Medical Research (PMR) to deliver Apolipoprotein E (APOE) genotyping services, even as shares closed down 5% at $8.58. APOE genotyping is a well-established area of genetic testing given the gene's known associations with both Alzheimer's disease risk and lipid metabolism.
Expanding Access to DiamiR's Testing Infrastructure
This collaboration enables PMR to utilize DiamiR's CAP- and CLEP-certified testing infrastructure within its clinical study frameworks. Certification of this kind signals that DiamiR's testing operations meet recognized quality and regulatory standards for clinical laboratory services, a detail that matters considerably for research organizations seeking a reliable, compliant partner for incorporating genetic testing into their clinical study protocols.
Applications Across Alzheimer's, Lipid Metabolism, and Cardiovascular Research
The resulting genetic insights will bolster translational research initiatives specifically centered on Alzheimer's disease, lipid metabolic processes, and cardiovascular wellness. APOE genotype is one of the most well-studied genetic risk factors across all three of these research areas, meaning the partnership positions DiamiR's testing services at the intersection of several active and clinically significant research fields simultaneously.
A Modest Stock Reaction to a Services Partnership
Despite the strategic relevance of this partnership to DiamiR's broader testing services business, the modest 5% decline in Niki BioSolutions shares suggests the market may be treating this as an incremental services contract rather than a transformative catalyst, a reasonable interpretation given that partnerships of this kind typically generate steady, ongoing service revenue rather than a single large, one-time financial impact.
Disclaimer: This article is for informational purposes only and does not constitute financial, investment, or trading advice. Readers should conduct their own research or consult a licensed financial advisor before making investment decisions. Past performance is not indicative of future results.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...